SOTIO Biotech: SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting

Patient enrollment and dosing ongoing in first-in-human study of BOXR1030 enhanced CAR T-cell therapy SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, will present

Related Keywords

United States ,Texas ,American ,Ecaterina Dumbrava ,Lisa Raffensperger ,Richard Kapsa ,University Of Texas Md Anderson Cancer Center ,American Society Of Clinical Oncology ,Clinical Oncology ,Assistant Professor ,Investigational Cancer Therapeutics ,Cancer Center ,Ihr Portfolio ,